Anthony Reiman

Dr. Anthony Reiman

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2014 in Cancer
Verified
Journal Article
Closed access
PDF file
ETEthan Toumishey
Ethan Toumishey
APAngeli Prasad
Angeli Prasad
GDGreg Dueck
Greg Dueck
NCNeil Chua
Neil Chua
DFDaygen Finch
Daygen Finch
ARAnthony Reiman
Anthony Reiman

22 June 2010 in Cancer
Verified
Journal Article
Closed access
PDF file
GDGreg Dueck
Greg Dueck
NCNeil Chua
Neil Chua
APAngeli Prasad
Angeli Prasad
DFDaygen Finch
Daygen Finch
DSDoug Stewart
Doug Stewart
ARAnthony Reiman
Anthony Reiman

6 April 2011 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
ARAnthony Reiman
Anthony Reiman
RLR. Lai
R. Lai
AVA. S. Veillard
A. S. Veillard
EPE. Paris
E. Paris
JSJ. C. Soria
J. C. Soria
PSP. Sève
P. Sève
Background: The IALT, JBR.10, ANITA and Cancer and Leukemia Group B 9633 trials compared adjuvant chemotherapy with observation for patients with resected non-small-cell lung cancer (R-NSCLC). Data from the metastatic setting suggest high tumor class III beta-tubulin (TUBB3) expression is a determinant of insensitivity to tubulin-targeting agents (e.g. vinorelbine, paclitaxel). In 265 patients from JBR.10 (vinorelbine–cisplatin versus observation), high TUBB3 was an adverse prognostic factor and was associated (nonsignificantly) with ‘greater’ survival benefit from chemotherapy. We explored this further in additional patients from JBR.10 and the other three trials. Patients and methods: TUBB3 immunohistochemical staining was scored for 1149 patients on the four trials. The original JBR.10 cut-off scores were used to classify tumors as TUBB3 high or low. The prognostic and predictive value of TUBB3 on disease-free survival (DFS) and overall survival (OS) was assessed by Cox models stratified by trial and adjusted for clinical factors. Results: High TUBB3 expression was prognostic for OS [hazard ratio (HR) = 1.27 (1.07–1.51), P = 0.008) and DFS [HR = 1.30 (1.11–1.53), P = 0.001). TUBB3 was not predictive of a differential treatment effect [interaction P = 0.20 (OS), P = 0.23 (DFS)]. Subset analysis (n = 420) on vinorelbine–cisplatin gave similar results. Conclusions: The prognostic effect of high TUBB3 expression in patients with R-NSCLC has been validated. We were unable to confirm a predictive effect for TUBB3.

12 November 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
HAHelmi Alfarra
Helmi Alfarra
JWJackson Weir
Jackson Weir
SGStacy Grieve
Stacy Grieve
ARAnthony Reiman
Anthony Reiman
Innate immune surveillance of cancer involves multiple types of immune cells including the innate lymphoid cells (ILCs). Natural killer (NK) cells are considered the most active ILC subset for tumor elimination because of their ability to target infected and malignant cells without prior sensitization. NK cells are equipped with an array of activating and inhibitory receptors (IRs); hence NK cell activity is controlled by balanced signals between the activating and IRs. Multiple myeloma (MM) is a hematological malignancy that is known for its altered immune landscape. Despite improvements in therapeutic options for MM, this disease remains incurable. An emerging trend to improve clinical outcomes in MM involves harnessing the inherent ability of NK cells to kill malignant cells by recruiting NK cells and enhancing their cytotoxicity toward the malignant MM cells. Following the clinical success of blocking T cell IRs in multiple cancers, targeting NK cell IRs is drawing increasing attention. Relevant NK cell IRs that are attractive candidates for checkpoint blockades include KIRs, NKG2A, LAG-3, TIGIT, PD-1, and TIM-3 receptors. Investigating these NK cell IRs as pathogenic agents and therapeutic targets could lead to promising applications in MM therapy. This review describes the critical role of enhancing NK cell activity in MM and discusses the potential of blocking NK cell IRs as a future MM therapy.

19 November 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
SGStacy Grieve
Stacy Grieve
Gabriel WajnbergGabriel Wajnberg
Gabriel Wajnberg
MLMiranda Lees
Miranda Lees
SCSimi Chacko
Simi Chacko
JWJackson Weir
Jackson Weir
ARAnthony Reiman
Anthony Reiman
Key Points: Expression of Hippo component TAZ is downregulated in MM through hypermethylation. TAZ reexpression, exogenously or pharmacologically, causes apoptosis and enhances sensitivity to anti-MM therapies by downregulating MYC.

10 October 2018 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
ARAnthony Reiman
Anthony Reiman
KSKerry J. Savage
Kerry J. Savage
MCMichael Crump
Michael Crump
MCMatthew C. Cheung
Matthew C. Cheung
DMDavid MacDonald
David MacDonald
AHAnnette E. Hay
Annette E. Hay
We investigated GDP (gemcitabine, 1000 mg/m2 IV d1, d8; dexamethasone, 40 mg po d1-4; cisplatin, 75 mg/m2 IV d1) combined with romidepsin on days 1 and 8 every 21 days to a maximum of six cycles in a standard 3 + 3, phase I dose escalation trial for patients with relapsed/refractory peripheral T-cell (PTCL) or diffuse large B-cell (DLBCL) lymphoma (NCT01846390). After treating four patients, gemcitabine and romidepsin were given on days 1 and 15 every 28 days. On the 21-day schedule at 6 mg/m2 romidepsin, there were three dose-limiting toxicities (DLTs) among four patients. On the 28-day schedule, there were no DLTs at the 6, 8, or 10 mg/m2 dose. At 12 mg/m2, there were four observed grade 3 DLTs among six evaluable patients. Full doses of GDP can be combined with a recommended phase II romidepsin dose of 10 mg/m2 if given on a day 1, 15 every 28 days schedule.